ZA200610572B - Method of treating granuloma annulare or sarcoid - Google Patents
Method of treating granuloma annulare or sarcoid Download PDFInfo
- Publication number
- ZA200610572B ZA200610572B ZA200610572A ZA200610572A ZA200610572B ZA 200610572 B ZA200610572 B ZA 200610572B ZA 200610572 A ZA200610572 A ZA 200610572A ZA 200610572 A ZA200610572 A ZA 200610572A ZA 200610572 B ZA200610572 B ZA 200610572B
- Authority
- ZA
- South Africa
- Prior art keywords
- lfa
- antibody
- administered
- antagonist
- granuloma annulare
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 55
- 201000005708 Granuloma Annulare Diseases 0.000 title claims description 47
- 201000000306 sarcoidosis Diseases 0.000 title claims description 10
- 239000005557 antagonist Substances 0.000 claims description 42
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 40
- 229960000284 efalizumab Drugs 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 230000003750 conditioning effect Effects 0.000 claims description 14
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 13
- 108010036949 Cyclosporine Proteins 0.000 claims description 13
- 229960001265 ciclosporin Drugs 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 229930182912 cyclosporin Natural products 0.000 claims description 12
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 12
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 11
- 229960004287 clofazimine Drugs 0.000 claims description 11
- 238000007920 subcutaneous administration Methods 0.000 claims description 11
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 10
- 238000011287 therapeutic dose Methods 0.000 claims description 10
- 230000003442 weekly effect Effects 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 9
- 101100341510 Mus musculus Itgal gene Proteins 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 108010008165 Etanercept Proteins 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 229960001334 corticosteroids Drugs 0.000 claims description 6
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 6
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 5
- 230000000977 initiatory effect Effects 0.000 claims description 5
- 229960005280 isotretinoin Drugs 0.000 claims description 5
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- 229960000860 dapsone Drugs 0.000 claims description 4
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims description 4
- 229960002199 etretinate Drugs 0.000 claims description 4
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960001476 pentoxifylline Drugs 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 229940073621 enbrel Drugs 0.000 claims description 3
- 102100022339 Integrin alpha-L Human genes 0.000 claims 6
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 25
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 11
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 201000004681 Psoriasis Diseases 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000013265 extended release Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 206010054094 Tumour necrosis Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010006784 Burning sensation Diseases 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960000403 etanercept Drugs 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- 239000008228 bacteriostatic water for injection Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 210000003701 histiocyte Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229940076664 close up Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- -1 glucocorticosteroids Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000002134 immunopathologic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
METHOD OF TREATING GRANULOMA ANNULARE OR SARCOID
The invention relates to treatment methods for granuloma annulare and sarcoid.
Granuloma annulare encompasses an uncommon benign group of granulomatous diseases that include localized, disseminated (generalized), subcutaneous, and perforating types. Approximately 10% to 15% of patients have disseminated granuloma annulare (DGA, also referred to as GGA), which occurs primarily in adults and is characterized by multiple discrete or confluent papules with either an annular or nonannular configuration." 3 DGA occurs predominantly on the trunk and proximal extremities, and patients with
DGA may present with hundreds of lesions. In approximately one third of cases, patients report symptoms of pruritus or burning sensations.? Histologically, DGA typically is characterized by areas of collagen alteration and elastic fiber degeneration in the middle and upper dermis surrounded by palisading inflammatory cells; the epidermis appears normal.’ The inflammatory infiltrates in DGA are primarily composed of a mixture of histiocytes (macrophages) and lymphocytes.
Although numerous theories have been proposed to explain the cause of granuloma annulare, the pathogenesis of this cutaneous disease remains unclear. Hypotheses include vasculitis, trauma-induced primary necrobiosis, monocytic release of lysosomal enzymes causing necrobiotic degeneration, and lymphocyte-mediated delayed hypersensitivity reaction (reviewed in Smith et al, 1997).” Several lines of evidence suggest a role for T- cell-mediated processes in the pathogenesis of granuloma annulare. Activated T lymphocytes, predominantly of the helper T (Th) cell phenotype, have been identified as the dominant lymphocyte in granuloma annulare infiltrates.®!! Activated Th cells secrete various proinflammatory cytokines, including interleukins, interferon-y (IFN-y), and tumor necrosis factor-a (TNF-a),'? all of which have been detected in granuloma annulare lesions." It has been suggested that initial infiltration of a minor, antigen-specific T- cell population (driven by the presence of unknown skin-specific antigens) is followed by recruitment of a large number of nonspecific T cells by means of nonspecific inflammatory cytokine and chemokine production. '*
Granuloma annulare lesions typically persist for 3 to 4 years, and following spontaneous resolution of lesions, relapse may occur.’ There is no standard treatment regimen or approach employed in the management of patients with granuloma annulare.
Furthermore, the response to long-term conventional treatment is generally poor, and in many cases, the risk of serious toxicity does not outweigh the benefits of treatment.
However, as DGA can be cosmetically disfiguring and as the lesions can persist indefinitely'’, many different therapies have been tried with varied success, including cyclosporine,'s!’ isotretinoin, '®?° etretinate,”’ topical and systemic corticosteroids, >? fumaric acid esters,?* psoralens plus ultraviolet A (PUVA), potassium iodide,”’** pentoxifylline,? topical vitamin E,*® hydroxychloroquine,*' dapsone,'®**** niacinamide,** low-dose chlorambucil, >? clofazimine,*” and a 5-lipoxygenase inhibitor plus vitamin E®
Many of these treatments are associated with potentially harmful side effects and require clinical and laboratory monitoring; due to their cumulative toxicity, many of these treatments cannot be administered chronically.
Thus, there is a need for a better method of treating granuloma annulare. The present invention satisfies this need and provides other benefits that will be apparent from the disclosure below.
The present invention provides a method of alleviating granuloma annulare conditions or sarcoid disease comprising administering to a patient having the disease, a therapeutically effective amount of an LFA-1 antagonist. The methods of the invention have the benefit of achieving rapid improvement and resolution of the disease and reduced side effects that are associated with conventional therapy for the disease. For example, conventional therapy with cyclosporine carries the risk of renal dysfunction and diarrhea may be a side effect with clofazimine treatment. The present method is effective to resolve the granuloma annulare within 2 months of initiation of therapy with the LFA-1 antagonist.
The granuloma annulare can be localized, disseminated (generalized; DGA), subcutaneous, or perforating type. In a specific embodiment, the granuloma annulare is disseminated granuloma annulare (DGA, also referred to as GGA).
In any of the methods of the present invention, in certain embodiments, the LFA-1 antagonist is an anti-LFA-antibody or an anti-ICAM 1 antibody. In one embodiment, the
5s LFA-1 antagonist is an anti-CD1 la antibody. In one embodiment, the anti-CD1 1a antibody is efalizumab.
In the present methods of alleviation, to minimize side effects, in particular infusion reactions on initial dosing, the patient can be administered the antagonist compound or antibody at an initial conditioning dose before the therapeutic dose, wherein the conditioning dose is lower than the therapeutic dose. Where the LFA-1 antagonist is efalizumab, the antibody can be administered at a dosage of between 0.3mg/kg to 4mg/kg. In one embodiment, the efalizumab antibody is administered at 1mg/kg weekly.
In another embodiment, efalizumab is administered at 2mg/kg weekly. Where the LFA-1 antagonist used is efalizumab, in one embodiment, the patient is administered a conditioning dose of efalizumab at 0.7mg/kg. In a further embodiment, the antibody is administered at an initial conditioning dose of 0.7mg/kg during the first week followed hy a dose of Img/kg weekly for at least 4 weeks. In separate embodiments, the patient is administered the weekly therapeutic dose of 1mg/kg or 2mg/kg for 8 weeks, 11 weeks, or 24 weeks
In any of the embodiments of the present methods of alleviating the disease, in a preferred embodiment, the LFA 1 antagonist is administered subcutaneously. In another embodiment the LFA 1 antagonist is administered intravenously.
In any of the embodiments of the method of alleviating granuloma annulare and sarcoid, the LFA 1 antagonist can be administered in conjunction with another therapy, a second therapeutic agent or an immunosuppressive agent. The second therapeutic agent is selected from the group consisting of cyclosporine, isotretinoin, etretinate, topical and systemic corticosteroids, fumaric acid esters, psoralens plus ultraviolet A (PUVA), potassium iodide, pentoxifylline, topical vitamin E, hydroxychloroquine, dapsone, niacinamide, low-dose chlorambucil, clofazimine, and a 5-lipoxygenase inhibitor plus vitamin E. In one embodiment, the second therapeutic agent is clofazimine or cyclosporine. Another second therapeutic agent is an immunoadhesin, in particular,
Enbrel® or Amevive®.
The second therapeutic agent and the LFA-1 antagonist can be administered consecutively, sequentially, or a combination of both, in either order.
Yet another aspect of the method of the invention is to alleviate granuloma annulare or sarcoid in a patient suffering from a relapse of the disease or a patient who is non-responsive to other therapy used to treat the disease.
In one embodiment, patient having the disease is experiencing an inadequate response or is non-responsive to cyclosporine or clofazimine treatment.
Also provided by the invention is an article of manufacture comprising a container containing an efalizumab composition, and a package insert indicating that the composition can be used to treat disseminated granuloma annulare.
FIG. 1A and 1B are photographs of the dorsum of the patient’s right hand, a spot previously affected by DGA showing excellent clearance and are representative of the patient’s overall response to treatment with the anti-CD11a antibody. FIG. 1B is a close- up of FIG. 1A.
Granuloma annulare encompasses an uncommon benign group of granulomatous diseases that include localized, disseminated (generalized), subcutaneous, and perforating types. Approximately 10% to 15% of patients have disseminated granuloma annulare (DGA), which occurs primarily in adults and is characterized by multiple discrete or confluent papules with either an annular or nonannular configuration. DGA occurs predominantly on the trunk and proximal extremities, and patients with DGA may present with hundreds of lesions. In approximately one third of cases, patients report symptoms of pruritus or burning sensations. Histologically, DGA typically is characterized by areas of collagen alteration and elastic fiber degeneration in the middle and upper dermis surrounded by palisading inflammatory cells; the epidermis appears normal. The inflammatory infiltrates in DGA are primarily composed of a mixture of histiocytes (macrophages) and lymphocytes. “Alleviating” in the context of the methods of the invention refers to therapeutic treatment wherein the object is to lessen the pathologic condition or disorder. A subject is successfully “alleviated” of a granuloma annulare disease if, after receiving a therapeutic amount of an LFA-1 antagonist of the invention according to the methods of the present invention, the subject shows observable and/or measurable reduction in or absence of one or more signs or symptoms of the disease as compared to baseline levels before receiving the treatment. The measurable signs or symptoms are for instance the size and number of skin lesions. Reduction of one or more symptoms of the disease may also be felt by the patient. Alleviation can achieve a complete response or resolution, defined as disappearance of all signs or symptoms, or a partial response. If the patient is not completely devoid of measurable signs and symptoms after receiving treatment, preferably the patient shows improvement in signs, symptoms of the disease by at least 20%, more preferably at least 40%, even more preferably at least 50%, more preferably by 70% or 75%, most preferably by 90% or greater, such as 95%, as compared to baseline measurements. These parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician of appropriate skill in the art. "Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. “Intermittent” administration is treatment that is done not consecutively without interruption, but rather is cyclic in nature.
A “conditioning dose” is a dose which attenuates or reduces the frequency or the severity of first dose adverse side effects associated with administration of a therapeutic compound. The conditioning dose may be a therapeutic dose, a sub-therapeutic dose. A therapeutic dose is a dose which exhibits a therapeutic effect on the patient and a sub- therapeutic dose is a dose which dose not exhibit a therapeutic effect on the patient treated.
A "therapeutically effective amount" refers to the minimum concentrations (amount) of an LFA-1 antagonist administered to a mammal that are effective in at least attenuating a pathological symptom (e.g. causing, inducing or resulting in a detectable / measurable improvement; lessen the severity, extent or duration of symptoms) which occurs as a result of the granuloma annulare disorder. The symptoms may vary with the types of granuloma annulare; however, the symptoms of a particular granuloma annulare disorder and the means of detecting or measuring improvement in the symptoms e.g, in the size and number of the skin lesions, will be familiar to the physician of skill in the art.
LFA-1 (leukocyte function associated antigen) is an integrin receptor involved in cell adherence interactions. LFA-1 consists of the a subunit CD11a and the f subunit
CD18. LFA-1 is expressed on all leukocytes.
The term "LFA-1 antagonist" generally refers to an antibody directed against either
CD11a or CD18 or both, but also includes ICAM-1, soluble forms of ICAM-1 (e.g., the
ICAM-1 extracellular domain, alone or fused to an immunoglobulin sequence), antibodies to ICAM-1, and fragments thereof, or other molecules capable of inhibiting the interaction of LFA-1 and ICAM-1.
Suitable LFA-1 antagonists include any compound which inhibits the interaction of
LFA-1 and a receptor therefor, in particular, ICAM-1. The LFA-1 antagonist may be a
5° small molecule, peptide, protein, immunoadhesin, an anti-LFA-1 antibody, or a fragment thereof, for example. These terms refer to antagonists directed against either CD11a or
CD18 or both. Preferably, the antagonist is directed to or binds to the CDI 1a subunit or
LFA-1 as a unit. Anti-CD11a antibodies include, e.g., MHM?24 [Hildreth ef al, Eur. J.
Immunol, 13: 202-208 (1983)], R3.1 (IgG1) [R. Rothlein, Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT], 25-3 (or 25.3), an IgGl available from
Immunotech, France [Olive et al., in Feldmann, ed., Human T cell Clones. A new
Approach to Immune Regulation, Clifton, NJ, Humana, 1986 p. 173], KBA (IgG2a) [Nishimura et al., Cell. Inmunol., 107: 32 (1987); Nishimura et al., ibid., 94: 122 (1985)],
M7/15 (IgG2b) [Springer et al., Immunol. Rev., 68: 171 (1982)], IOT16 [Vermot
Desroches et al., Scand. J. Immunol, 33: 277-286 (1991)], SPVL7 [Vermot Desroches et al., supra}, and M17 (IgG2a) also referred to as M17/4, available from ATCC, (hybridoma
Accession no. TIB-217) which are rat anti-murine CD11a antibodies. A preferred anti-
CD11a antibody is a humanized antibody, efalizumab (Raptiva™; Genentech, CA). Other preferred anti-CD11a antibodies are the humanized antibodies described in U.S. Patent 6,037,454. It is also generally preferred that the anti-CD1 1a antibodies are not T-cell depleting antibodies, that is, that the administration of the anti-CD1 1a antibody does not reduce the level of circulating T-cells.
In one embodiment, the humanized anti-CD1 1a antibody is one that comprises the
VL sequence of
DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWYQQKPGKAPKLLIYSGSTLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIK (SEQ ID
NO. 1), and the VH sequence of
EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGMIHP
SDSETRYNQKFKDRFTISVDKSKNTLY LQMNSLRAEDTAVYYCARGIYFYGTTYF
DYWGQGTLVTVSS (SEQ ID NO. 2); or
In another embodiment, the anti-CD11a antibody is one that comprises the MHM?24 VL sequence
DVQITQSPSYLAASPGETISINCRASKTISKYLAWYQEKPGKTNKLLIYSGSTLQSGI
PSRFSGSGSGTDFTLTISSLEPEDFAMYYCQQHNEYPLTFGTGTKLELK (SEQ ID
NO. 3), and 40
MHM?24 VH sequence
EVQLQQPGAELMRPGASVKLSCKASGYSFTGHWMNWVRQRPGQGLEWIGMIHP
SDSETRLNQKFKDKATLTVDKSSSSAYMQLSSPTSEDSAVYYCARGIYFYGTTYF
45 DYWGQGTTLTVSS (SEQ ID NO. 4).
Examples of anti-CD18 antibodies include MHM23 [Hildreth ef al., supra], M18/2 (IgG2a) [Sanches-Madrid et al., J. Exp. Med., 158: 586 (1983)], H52 [Fekete eral, J.
Clin, Lab Immunol., 31: 145-149 (1990)], Mas191c [Vermot Desroches et al., supra],
I0T18 [Vermot Desroches et al., supra), 60.3 [Taylor et al., Clin. Exp. Immunol., 71: 324-328 (1988)], and 60.1 [Campana et al., Eur. J. Immunol., 16: 537-542 (1986)]. See also US 5,997,867.
Other examples of suitable LFA-1 binding molecules, including antibodies, are described in Hutchings et al., supra, WO 98/51343, WO 91/18011, WO 91/16928, WO 91/16927, Can. Pat. Appln. 2,008,368, WO 90/15076, WO 90/10652, WO 90/13281, WO 93/06864, WO 93/21953, EP 387,668, EP 379,904, EP 346,078, US 5,932,448, US 5,622,700, US 5,597,567, U.S. 5,071,964, U.S. 5,002,869, US 5,730,983, Australian Pat.
Appln. 8815518, FR 2700471 A, EP 289,949, EP 362526, and EP 303,692.
A "small molecule" is defined herein to have a molecular weight below about 600 daltons, and is generally an organic compound. “Efalizumab”’(Raptiva®) is a recombinant humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a (US patent no. 6,037,454).
Commercially available from Genentech, Inc., Raptiva is an FDA approved drug for psoriasis treatment. Efalizumab binds with high specificity and affinity to CD11a, the a subunit of leukocyte function-associated antigen 1 (LFA-1) on the surface of T cells, preventing LFA-1 from binding with one of its ligands, intercellular adhesion molecule-1 (ICAM-1), and inhibiting multiple T-cell interactions. Interaction between LFA-1 and
ICAM-1 contributes to the initiation and maintenance of multiple processes, including activation of T-lymphocytes, adhesion of T-lymphocytes to endothelial cells, and migration of T-lymphocytes to sites of inflammation including psoriatic and granulomatous skin.
RAPTIVA® (efalizumab) is supplied as a sterile, lyophilized powder in single-use glass vials for subcutaneous (SC) injection. Reconstitution of the single-use vial with 1.3 mL of the supplied sterile water for injection yields 100 mg/mL of RAPTIVA. Each single-use vial of RAPTIVA contains 150 mg of efalizumab, 123.2 mg of sucrose, 6.8 mg of L-histidine hydrochloride monohydrate, 4.3 mg of L-histidine and 3 mg of polysorbate 20 and is designed to deliver 125 mg of efalizumab in 1.25 mL. “ENBREL” (etanercept; Amgen, CA) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgGl. Etanercept binds specifically to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors. It inhibits the activity of TNF.
The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity or function. "Antibody fragments" comprise a portion of a full length antibody, generally the antigen binding or variable region thereof . Examples of antibody fragments include Fab, Fab', F(ab"), and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S.
Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352:624-628 (1991) and Marks et al., J. Mol. Biol. 222:581-597 (1991), for example. “Functional fragments” of the antagonist antibodies of the invention are those fragments that retain binding to LFA-1, CD11a, or their ligand with substantially the same affinity as the intact full length molecule from which they are derived and show biological activity.
"Chimeric" antibodies (immunoglobulins) have a portion of the heavy and/or light chain identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodics derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). Humanized antibody as used herein is a subset of chimeric antibodies. "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin.
For the most part, humanized antibodies are human immunoglobulins (recipient or acceptor antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody.
These modifications are made to further refine antibody performance such as binding affinity. Generally, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence although the FR regions may include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones ef al., Nature 321:522-525 (1986),
Reichmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593- 596 (1992).
An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
Compositions and Methods of the Invention
According to one embodiment, the LFA-1antagonist is an immunoadhesin, e.g.,
Amevive® (Biogen, Boston, MA)
In the methods of treatment of the present invention, the LFA-1 antagonist can be administered chronically or intermittently.
The patient can be treated with the LFA-1 antagonists in conjunction with one or more therapeutic agents. Second therapeutic agents useful in the treatment of granuloma annulare include the following: cyclosporine, isotretinoin, etretinate, topical and systemic corticosteroids, fumaric acid esters, psoralens plus ultraviolet A (PUVA), potassium iodide, pentoxifylline, topical vitamin E, hydroxychloroquine, dapsone, niacinamide, low- dose chlorambucil, clofazimine, and a 5-lipoxygenase inhibitor plus vitamin E. “Immunosuppressive agent” as used herein refers to substances that act to suppress or mask the immune system of a patient. Such agents would include substances that suppress cytokine production, down regulate or suppress self-antigen expression, or mask the MHC antigens. Examples of such agents include steroids such as glucocorticosteroids, e.g., prednisone, methylprednisolone, and dexamethasone; 2-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No. 4,665,077), azathioprine (or cyclophosphamide, if there is an adverse reaction to azathioprine); bromocryptine; glutaraldehyde (which masks the
MHC antigens, as described in U.S. Pat. No. 4,120,649); anti-idiotypic antibodies for
MHC antigens and MHC fragments; cyclosporin A; cytokine or cytokine receptor antagonists including anti-interferon-v, -B, or -a antibodies; anti-tumor necrosis factor-a antibodies; anti-tumor necrosis factor-f antibodies; anti-interleukin-2 antibodies and anti-
IL-2 receptor antibodies; anti-L3T4 antibodies; heterologous anti-lymphocyte globulin; pan-T antibodies, preferably anti-CD3 or anti-CD4/CD4a antibodies; soluble peptide containing a LFA-3 binding domain (WO 90/08187 published 7/26/90); streptokinase;
TGF-p; streptodornase; RNA or DNA from the host; FK506; RS-61443; deoxyspergualin; rapamycin; T-cell receptor (U.S. Pat. No. 5,114,721); T-cell receptor fragments (Offner et al, Science 251:430-432 (1991); WO 90/11294; and WO 91/01133); and T cell receptor antibodies (EP 340,109) such as T10B9. The immunosuppressive agents hercin may overlap with the second therapeutic agent.
Dosing
For the methods of the invention, the antagonists and antibodies of the invention will be administered at a dosage that is efficacious for the treatment of the granuloma annulare or sarcoid disease while minimizing toxicity and side effects.
The LFA-1 antibodies can be administered to the patient in a dosage range of about
Img/kg to 20mg/kg. In different embodiments, the dosage range is 1-15mg/kg, 1- 10mg/kg, 2-10mg/kg, 3-10mg/kg. Efalizumab antibody can be administered at a dosage range of from 0.3mg/kg to 4 mg/kg, at least once a week for at least 4 weeks.
Doses of efalizumab of up to 4 mg/kg/wk SC for 10 weeks following a conditioning (0.7 mg/kg) first dose have been administered without an observed increase in acute toxicity.
In one embodiment, efalizumab is administered to the patient subcutaneously as an initial conditioning dose of 0.7 mg/kg followed by 11 weekly SC (subcutaneous) doses of 1 mg/kg/wk. The initial lower conditioning dose is optional; the patient can receive instead 12 weekly doses at 1 mg/kg/wk.
In treating disease, the LFA-1 antagonists of the invention can be administered to the patient chronically or intermittently, as determined by the physician of skill in the disease.
A patient administered a drug by intravenous infusion or subcutaneously may experience adverse events such as fever, chills, burning sensation, asthenia and headache.
To alleviate or minimize such adverse events, the patient may receive an initial conditioning dose(s) of the antibody followed by a therapeutic dose. The conditioning dose(s) will be lower than the therapeutic dose to condition the patient to tolerate higher dosages.
"Initial" dosing means dosing that is not the last dosing administered in the treatment. The initial dosing need not be a single dose, but it is not the last dose. "Subsequent" dosing is dosing that follows the initial dosing and includes the last dose administered for the treatment.
Route of administration :
The antagonists and antibodies as well as second therapeutic agents and immunosuppressive agents used in the methods of the invention are administered to a human patient in accord with methods known to medical practitioners, such as by intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by subcutaneous, topically, intramuscular, intra-arterial, intrapulmonary, intra- articular, intrasynovial, intrathecal, intralesional, or inhalation routes (e.g., intranasal), generally by subcutaneous, intravenous or topical administration. _ The LFA-1 antagonist, the second therapeutic agent and immunosuppressive agent can be provided systemically or topically. In one embodiment, the LFA-1 antagonist is administered topically.
Pharmaceutical Formulations
Therapeutic formulations of the antagonists and antibodies used in accordance with the present invention are prepared for storage by mixing the compound or antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as olyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non- ionic surfactants such as TWEENTM, PLURONICS™ or polyethylene glycol (PEG).
The LFA-1 antagonists useful in the methods of the present invention can be provided in an extended release formulation.
The term "extended-release" or "sustained-release" formulations in the broadest possible sense means a formulation of an active LFA-1 antagonist compound resulting in the release or activation of the compound for a sustained or extended period of time or at least for a period of time which is longer than if the compound was made available in vivo in the native or unformulated state. Optionally, the extended-release formulation occurs at a constant rate and/or results in sustained and/or continuous concentration of the active polypeptide. Suitable extended release formulations may comprise microencapsulation, semi-permeable matrices of solid hydrophobic polymers, biogradable polymers, biodegradable hydrogels, suspensions or emulsions (e.g., oil-in-water or water-in-oil).
Optionally, the extended-release formulation comprises poly-lactic-co-glycolic acid (PLGA) and can be prepared as described in Lewis, "Controlled Release of Bioactive
Agents form Lactide/Glycolide polymer," in Biodegradable Polymers as Drug Delivery
Systems, M. Chasin & R. Langeer, Ed. (Marcel Dekker, New York), pp. 1-41. Optionally, the extended-release formulation is stable and the activity of the LFA-1 antagonist does not appreciably diminish with storage over time. More specifically, such stability can be enhanced through the presence of a stabilizing agent such as a water-soluble polyvalent metal salt.
Articles of Manufacture and Kits
Another embodiment of the invention is an article of manufacture containing materials useful for the treatment of granuloma annulare or sarcoid disease. The article of manufacture comprises at least one container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc.
The containers may be formed from a variety of materials such as glass or plastic. At least one container holds a composition which is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). Two therapeutic compositions may be provided in the article of manufacture. At least one active agent in the first composition is a CD11a binding antibody of the invention. The second or second and third compositions may be held in one or more separate containers. The label or package insert indicates that the composition is used for treating granuloma annulare,
DGA or sarcoid. The label or package insert will further comprise instructions for administering the compositions to the patient. Package insert refers to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products. Additionally, the article of manufacture may further comprise a container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline,
Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
In a specific embodiment, the container contains an efalizumab composition, and the package insert indicates that the composition can be used to treat disseminated granuloma annulare (DGA). - Experimental Examples
This report describes a case of a patient with moderate to severe psoriasis with severe DGA that resolved upon treatment with efalizumab (anti-CD11a), a novel biologic
T-cell modulator.
A 52-year old male with a history of moderate to severe plaque psoriasis was first diagnosed with granuloma annulare in 1999, with lesions initially appearing on his hands.
A review of his medical history revealed that he did not have diabetes mellitus, a disease state with questionable association with granuloma annulare. Within months of his initial diagnosis, the lesions spread to his arms, shoulders, and neck.
In December 1999, the DGA lesions were biopsied, confirming the diagnosis of
DGA. From March 2000 through October 2002, this patient was treated with numerous agents in an attempt to manage his plaque psoriasis and DGA, including systemic therapies such as cyclosporine and clofazimine; intralesional corticosteroids; psoralen plus ultraviolet A (PUVA); and topical therapies such as corticosteroids, desoximetasone, tazarotene, clobetasol propionate, and tacrolimus ointment, all with varying levels of efficacy. Control of this patient’s plaque psoriasis and DGA were further complicated by s the development of renal dysfunction related to cyclosporine and intolerance secondary to clofazimine-induced diarrhea.
In October 2002, this patient was enrolled into an efalizumab Phase III clinical trial for patients with moderate to severe plaque psoriasis. All psoriasis therapies were discontinued as he entered the 4-week washout phase prior to administration of study drug. In November 2002, the patient began efalizumab therapy (anti-CD11a monoclonal antibody) at a dose of 1mg/kg weekly, for 12 weeks, by subcutaneous injection. The baseline Psoriasis Arca and Severity Index (PASI) was 12.6. The planned duration of study therapy was 12 weeks followed by extended open-label treatment for up to an additional 48 weeks of continuous therapy at a dose of 1 mg/kg/wk. Following initiation 1s of efalizumab therapy, the patient’s DGA cleared rapidly, with marked improvement noted within 4 weeks of initiating efalizumab therapy. By January, the DGA was resolved (see
Figure 1). In April 2003, the clofazimine was discontinued. As of July 2003, the DGA remains in remission, with the exception of post-inflammatory pigmentation, and the patient’s PASI scores remained markedly improved and at the level achieved at Week 12, 20 demonstrating maintenance of the improvement achieved at the completion of efalizumab therapy.
Within 2 months after receiving efalizumab, the patient’s DGA had resolved. This is the first case report of rapid and successful treatment of severe DGA with an exemplary
LFA-1 antagonist, efalizumab. 25
References cited within this application, including patents, published applications and other publications, are hereby incorporated by reference. 1. Friedman-Bimbaum R. Generalized and localized granuloma annulare. Int J 30 Dermatol. 1986;25:364-366. 2. Dabski K, Winkelmann RK. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol. 1989;20:39-47. 3. Muhlbauer JE. Granuloma annulare. J Am Acad Dermatol. 1980;3:217-230. 4. Dabski K, Winkelmann RK. Generalized granuloma annulare: histopathology and 35 immunopathology. Systematic review of 100 cases and comparison with localized granuloma annulare. J Am Acad Dermatol. 1989;20:28-39.
S. Friedman-Bimbaum R, Weltfriend S, Kemer H, Lichtig C. Elastic tissue changes in generalized granuloma annulare. Am J Dermatopathol. 1989;11:429-433. 6. Hanna WM, Moreno-Merlo F, Andrighetti L. Granuloma annulare: an elastic tissue disease? Case report and literature review. Ultrastruct Pathol. 1999;23:33-38. 7. Smith MD, Downie JB, DiCostanzo D. Granuloma annulare. Int J Dermatol. 1997,36:326-333. 8. Buechner SA, Winkelmann RK, Banks PM. Identification of T-cell subpopulations in granuloma annulare. Arch Dermatol. 1983;119:125-128. 9. Modlin RL, Vaccaro SA, Gottlieb B, Gebhard JF, Linden CE, Forni M et al.
Granuloma annulare. Identification of cells in the cutaneous infiltrate by immunoperoxidase techniques. Arch Pathol Lab Med. 1984;108:379-382. 10. Modlin RL, Horwitz DA, J ordan RR, Gebhard JF, Taylor CR, Rea TH.
Immunopathologic demonstration of T lymphocyte subpopulations and interleukin 2 "in granuloma annulare. Pediatr Dermatol. 1984;2:26-32. 11. Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ et al. © Expression of IFN, coexpression of TNFO and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol
Res. 2000;292:384-390. 12. Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000;343:108-117. 13. Ahmed AA, Nordlind K, Schultzberg M, Liden S. Interleukin-1 alpha- and beta-, interleukin-6- and tumour necrosis factor-alpha-like immunoreactivities in chronic granulomatous skin conditions. Acta Derm Venereol. 1994,74:435-440. 14. Mempel M, Musette P, Flageul B, Schnopp C, Remling R, Gachelin G et al. T-cell receptor repertoire and cytokine pattern in granuloma annulare: defining a particular type of cutaneous granulomatous inflammation. J Invest Dermatol. 2002,118:957- 966. 15. Barron DF, Cootauco MH, Cohen BA. Granuloma annulare. A clinical review.
Lippincotts Prim Care Pract. 1997;1:33-39. 16. Filotico R, Vena GA, Coviello C, Angelini G. Cyclosporine in the treatment of generalized granuloma annulare. J Am Acad Dermatol. 1994,30:487-488. . 17. Ho VC. Cyclosporine in the treatment of generalized granuloma annulare. J Am
Acad Dermatol. 1995;32(2 Pt 1):298.
18. Schleicher SM, Milstein HJ, Lim SJ, Stanton CD. Resolution of disseminated granuloma annulare with isotretinoin. /nt J Dermatol. 1992;31:371-372. 19. Tang WYM, Chong LY, Lo KK. Resolution of generalized granuloma annulare with isotretinoin therapy. Int J Dermatol. 1996;35:455-456. 20. Adams DC. Improvement of chronic generalized granuloma annulare with isotretinoin. Arch Dermatol. 2002;138:1518-1519. 21. Botella-Estrada R, Guillen C, Sanmartin O, Aliaga A. Disseminated granuloma annulare: resolution with etrctinate therapy. J Am Acad Dermatol. 1992;26:777-778. 22. Takigawa M, Aoshima T. Generalized granuloma anulare in a 15-month-old infant.
Dermatologica. 1976;153:202-206. 23. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol. 1992:72:69-71. 24. Kreuter A, Gambichler T, Altmeyer P, Brockmeyer NH. Treatment of disseminated granuloma annulare with fumaric acid esters. BMC Dermatol. 2002;2:5. 25. Kerker BJ, Huang CP, Morison WL. Photochemotherapy of generalized granuloma annulare. Arch Dermatol. 1990;126:359-361. 26. Setterfield J, Huilgol SC, Black MM. Generalised granuloma annulare successfully treated with PUVA. Clin Exp Dermatol. 1999;24:458-460. 27. Giessel M, Graves K, Kalivas J. Treatment of disseminated granuloma annulare with potassium iodide. Arch Dermatol. 1979;115:639-640. 28. Smith JB, Hansen CD, Zone JJ. Potassium iodide in the treatment of disseminated granuloma annulare. J 4m Acad Dermatol. 1994;30:791-792. 29. Rubel DM, Wood G, Rosen R, Jopp-McKay A. Generalised granuloma annulare successfully treated with pentoxifylline. Australas J Dermatol. 1993;34:103-108. 30. Burg G. Disseminated granuloma anulare: therapy with vitamin E topically.
Dermatology. 1992;184:308-309. 31. Carlin MC, Ratz JL. A case of generalized granuloma annulare responding to hydroxychloroquine. Cleve Clin J Med. 1987,54:229-232. 32. Saied N, Schwartz RA, Estes SA. Treatment of generalized granuloma annulare with dapsone. Arch Dermatol. 1980;116:1345-1346. 33. Czarnecki DB, Gin D. The response of generalized granuloma annulare to dapsone.
Acta Derm Venereol. 1986;66:82-84.
34. Ma A, Medenica M. Response of generalized granuloma annulare to high-dose niacinamide. Arch Dermatol. 1983;119:836-839. 35. Kossard S, Winkelmann RK. Low-dose chlorambucil in the treatment of generalized granuloma annulare. Dermatologica. 1979,158:443-450. 36. Rudolph RI. Disseminated granuloma annulare treated with low-dose chlorambucil.
Arch Dermatol. 1979;115:1212-1213. 37. Antony F, Holden CA. Sweet's syndrome in association with generalized granuloma annulare in a patient with previous breast carcinoma. Clin Exp Dermatol. 2001;26:668-670. 38. Smith KJ, Norwood C, Skelton H. Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E. Br J Dermatol. 2002;146.667-670. 39. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T et al.
Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996;157:4986-4995.
C18
Claims (28)
1. A method of alleviating a granuloma annulare or a sarcoid disease comprising administering to a patient having the disease, a therapeutically effective amount of an LFA 1 antagonist.
2. The method of claim 1, wherein the granuloma annulare is selected from the group consisting of localized, disseminated (generalized), subcutaneous, and perforating disease types.
3. The method of claim 2, wherein the granuloma annulare is disseminated granuloma annulare.
4. The method of any of the preceding claims wherein the LFA-1 antagonist is an anti-LFA-antibody.
5. The method of any of claims 1-3, wherein the LFA-1 antagonist is an anti- ICAM 1 antibody.
6. The method of claim 4 wherein the anti-LFA-antibody is an anti-CD11a antibody.
7. The method of claim 6, wherein the anti-CD1 1a antibody is efalizumab.
8. The method of claim 7, wherein the antibody is administered at between
0.3mg/kg to 4mg/kg.
9. The method of claim 8, wherein the antibody is administered at Img/kg weekly.
10. The method of claim 8, wherein the antibody is administered at 2 mg/kg weekly.
‘11. The method of claim 8 or 9, wherein the patient is administered the antibody at an initial conditioning dose before the therapeutic dose.
12. The method of claim 11, wherein the conditioning dose is 0.7mg/kg.
13. The method of claim 7, wherein the antibody is administered at an initial conditioning dose of 0.7mg/kg during the first week followed by a dose of 1mg/kg weekly for at least 4 weeks.
14. The method of claim 13, wherein the dose of 1mg/kg is administered for at least 11 weeks.
15. The method of claim 1, wherein the LFA 1 antagonist is administered subcutaneously.
16. The method of any one of claims 9, 10,14, wherein the LFA 1 antagonist is administered subcutaneously.
17. The method of claim 1 wherein the LFA 1 antagonist is administered “intravenously.
18. The method of claims 1 or 7 wherein the LFA 1 antagonist is administered in conjunction with a second therapeutic agent or an immunosuppressive agent.
19. The method of 18, wherein the second therapeutic agent is selected from the group consisting of cyclosporine, isotretinoin, etretinate, topical and systemic corticosteroids, fumaric acid esters, psoralens plus ultraviolet A (PUVA), potassium iodide, pentoxifylline, topical vitamin E, hydroxychloroquine, dapsone, niacinamide, low- dose chlorambucil, clofazimine, and a S-lipoxygenase inhibitor plus vitamin E.
20. The method of 19, wherein the second therapeutic agent is clofazimine or cyclosporine
21. The method of 19, wherein the second therapeutic agent is Enbrel® or Amevive®.
22. The method of claim 19, wherein the second therapeutic agent and the LFA-1 antagonist are administered concurrently.
23. The method of claim 19, wherein the second therapeutic agent and the LFA-1 antagonist are administered sequentially in either order.
24. The method of claim 19, wherein the second therapeutic agent and the LFA-1 antagonist are administered in a combination of concurrently and sequentially in either order.
25. The method of any one of the preceding claims wherein the patient is suffering from a relapse of the disease.
26. The method of any one of the preceding claims wherein the patient is non- responsive to other therapy.
27. The method of any one of the preceding claims wherein the granuloma annulare is resolved within 2 months of initiation of therapy with the LFA-1 antagonist.
28. An article of manufacture comprising a container containing an efalizumab composition, and a package insert indicating that the composition can be used to treat disseminated granuloma annulare.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57876804P | 2004-06-09 | 2004-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200610572B true ZA200610572B (en) | 2008-06-25 |
Family
ID=38693335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200610572A ZA200610572B (en) | 2004-06-09 | 2005-06-08 | Method of treating granuloma annulare or sarcoid |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101001880A (en) |
ZA (1) | ZA200610572B (en) |
-
2005
- 2005-06-08 ZA ZA200610572A patent/ZA200610572B/en unknown
- 2005-06-08 CN CN 200580027176 patent/CN101001880A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101001880A (en) | 2007-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11560434B2 (en) | Formulation for anti-α4β7 antibody | |
US11071780B2 (en) | Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab | |
TWI462744B (en) | Steroid sparing agents and methods of using same | |
US20210205410A1 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
US7396530B2 (en) | Method of treating granuloma annulare or sarcoid | |
MX2012010612A (en) | Compositions and methods useful for stabilizing protein-containing formulations. | |
US11104730B2 (en) | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors | |
KR20200143718A (en) | Anti-CD40 antibody for use in preventing graft rejection | |
ZA200610572B (en) | Method of treating granuloma annulare or sarcoid | |
KR20070022387A (en) | Method of treating granuloma annulare or sarcoid | |
AU2018266324B2 (en) | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors | |
EP1854480A2 (en) | Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist | |
KR20220082000A (en) | A pharmaceutical composition used for the prevention and/or treatment of acquired hemophilia A, and a product comprising the pharmaceutical composition | |
JP2022553493A (en) | Methods for Preventing Human Virus-Related Disorders in Patients | |
EA043390B1 (en) | METHODS FOR TREATING EYE DISEASES WITH APLNR ANTAGONISTS AND VEGF INHIBITORS | |
NZ617340B2 (en) | Formulation for anti-?4?7 antibody |